Novartis AG (NVS)

90.78
0.27 0.30
NYSE : Health Technology
Prev Close 90.51
Open 90.28
Day Low/High 90.26 / 90.95
52 Wk Low/High 72.30 / 92.39
Volume 1.06M
Avg Volume 2.19M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 231.38B
EPS 5.50
P/E Ratio 16.87
Div & Yield 1.86 (2.77%)

Latest News

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

This will be the craziest reporting season we've seen in ages, says Jim Cramer. He's got your game plan for next week.

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.

Novartis Stock Is Poised to Rise Another 15% From Here

Novartis Stock Is Poised to Rise Another 15% From Here

The stock's performance has been impressive in the past three months.

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Tilray Jumps 10% on AB InBev Partnership

Tilray Jumps 10% on AB InBev Partnership

Legal-marijuana firm surges on deal with Budweiser parent AB InBev to develop cannabis-based drinks.

Tilray Is Now a Top-Tier Cannabis Play

Tilray Is Now a Top-Tier Cannabis Play

I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.

Tilray Stock Burns Higher With Anheuser-Busch Beverage Deal

Tilray Stock Burns Higher With Anheuser-Busch Beverage Deal

Pot stock partnerships are a gateway to gains for cannabis investors.

Thoughts on the Cannabis Industry and Our Related Positions

Some ancillary help came trickling through the door Tuesday, with possibly more on the way.

Tilray Shares Surge on Novartis Distribution Deal

Tilray Shares Surge on Novartis Distribution Deal

Canadian cannabis producer's stock jumps on announcement that it's teaming up with Novartis's Sandoz until to sell and distribute medical cannabis products globally.

Tilray Stock Higher Ahead of First Post-Legalization Earnings Release

Tilray Stock Higher Ahead of First Post-Legalization Earnings Release

Tilray will have a lot to tackle this evening.

Novartis Data At ASH And SABCS Show Strength Of Pipeline And Portfolio In Hematology And Oncology

Novartis Data At ASH And SABCS Show Strength Of Pipeline And Portfolio In Hematology And Oncology

- Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Stocks fall sharply on Thursday after a hawkish set of minutes from last month's Federal Reserve meeting cements the case for near-term interest rate hikes.

Novartis Secures Prostate Cancer Treatment With Endocyte Deal

Novartis Secures Prostate Cancer Treatment With Endocyte Deal

The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.

A Reckless Fed: Market Recon

A Reckless Fed: Market Recon

It's time for the central bank to show the same level of concern for their misplaced aggression.

Facebook, Fed Minutes, AmEx, PayPal and Endocyte - 5 Things You Must Know

Facebook, Fed Minutes, AmEx, PayPal and Endocyte - 5 Things You Must Know

U.S. stock futures decline after a hawkish set of minutes from last month's Federal Reserve meeting; American Express, PayPal and Travelers report earnings; Facebook believes hack was done by spammers, says a report; Novartis to buy Endocyte for $2.1 billion.

Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG

Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG

Tesla will pay $20 million as part of the settlement with Elon Musk paying another $20 million.

Tilray Jumps After $200 Price Target and Bullish Rating at Benchmark

Tilray Jumps After $200 Price Target and Bullish Rating at Benchmark

The rating is based on an analysts' view that Wednesday's full legalization of cannabis in Canada will be a boon for the company.

Novartis Analysis Shows Crizanlizumab (SEG101) Increased The Number Of Patients Free Of Sickle Cell Pain Crises Vs Placebo During SUSTAIN Study

Novartis Analysis Shows Crizanlizumab (SEG101) Increased The Number Of Patients Free Of Sickle Cell Pain Crises Vs Placebo During SUSTAIN Study

- Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

With 38 million Americans suffering from migraines, the FDA's approval of Eli Lilly's preventative migraine drug Emgality can help them get their lives back. We spoke with Christi Shaw, president, Lilly Bio-Medicines for all the details.

Novartis Is Ready to Rally From a Large Base Pattern

Novartis Is Ready to Rally From a Large Base Pattern

Let's check out the latest charts and indicators for some technical guidance.

Jim Cramer: Reefer Madness

Jim Cramer: Reefer Madness

Tilray's a disruptive company for many industries.

Teva Shares Pop as FDA Approves Its Migraine Drug

Teva Shares Pop as FDA Approves Its Migraine Drug

Ajovy is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the FDA to prevent migraines.

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.

Biotech Stocks Getting Their Due Respect

Biotech Stocks Getting Their Due Respect

Here are two I think will bounce back before the end of the year.

TheStreet Quant Rating: B+ (Buy)